L-Annamycin + Cytarabine in Relapsed/Refractory AML

L-Annamycin is a novel anthracycline from micro-cap Moleculin (MBRX). Phase 1B/2 showed promising 50% CR in 2L and 40% blinded CRc in first 30 MIRACLE pts. However: tiny sponsor with limited resources, R/R AML is extremely difficult, trial is only recruiting (1206 days to completion), adaptive Phase 2/3 design adds complexity, and 312-patient enrollment across multiple countries is ambitious for MBRX. Prior Phase 2 data is encouraging but small (n=22). Interim unblinding mid-2026 is a near-term catalyst but final results are years away.

Adaptive randomized blinded design and a remission endpoint in relapsed AML are sensible, but this is an early pivotal program with dose-selection complexity, small biotech execution risk, and a long path before a definitive superiority readout.

Adaptive Ph2/3 randomized double-blind placebo-controlled design with Part A dose selection (190 vs 230 mg/m2 L-Annamycin) using CR rate then Part B superiority test. Targets R/R AML after one prior line with high unmet need and typically modest control arm CR rates. Objective primary endpoint of CR after one cycle (up to Day 49) is early and clear. Recruiting well (est 312 pts, multi-country) b/o

Adaptive Ph2/3 randomized double-blind placebo-controlled design with Part A (1:1:1 randomization) selecting optimal L-Annamycin dose (190 vs 230 mg/m2) by CR rate before Part B superiority test. r/r AML after 1 prior line is challenging population but primary CR endpoint after 1 cycle (to day 49) is objective and early. Prior Ph1/2 showed 36-60% CR/CRi in 2L setting; preliminary blinded CRc 40% (

Prior Phase 1/2 data showed a 50% complete remission (CR) rate in 2nd-line AML for Annamycin + cytarabine. Feb 2026 blinded data from the 2:1 randomized MIRACLE trial revealed a 40% CRc rate in the first 30 patients. Assuming control performs near its historical ~18% rate, Annamycin is driving the robust efficacy, making primary endpoint success highly probable.

R/R AML is notoriously difficult to treat with low success rates for novel agents in pivotal trials. Although Annamycin is designed to evade multidrug resistance, an adaptive Phase 2/3 presents high efficacy hurdles and significant operational/funding risks for a microcap sponsor over a 3-year timeline.

R/R AML is a notoriously difficult indication with a high historical failure rate in pivotal trials. While Annamycin's design to evade multidrug resistance is interesting, demonstrating statistically significant superiority over placebo + cytarabine in a Phase 3 setting will be highly challenging.

Phase 2/3 trial in relapsed/refractory AML, a difficult population. Adaptive design and dose selection add complexity. Primary endpoint is complete remission rate; prior data for L-Annamycin is limited. High risk of failure in pivotal portion.

Adaptive pivotal design in high-risk r/r AML is challenging. Primary endpoint is objective (CR rate), but L-Annamycin's prior data is limited. Sponsor is small-cap. Part A dose selection adds complexity. Overall odds are below 50%.

L-annamycin shows promise in Phase 1/2 for relapsed AML with non-cardiotoxic profile, but pivotal Phase 3 success rates for AML remain low historically (~35%). The adaptive design mitigates dose selection risk, but placebo-controlled superiority in this refractory population is a high hurdle. Long timeline to 2029 adds significant execution risk.

Pivotal AML trial faces high historical failure rates for R/R patients. While L-annamycin's non-cardiotoxic profile is promising, the primary endpoint of CR rate after one cycle is aggressive. Phase 2/3 adaptive design introduces operational complexity and placebo-controlled superiority is a high bar. Dose selection in Part A adds risk before Part B expansion.

Pivotal adaptive Phase 2/3 trial with uncertain outcomes, limited prior data on L-Annamycin, and high relapse rate in AML patients.

Phase 2/3 adaptive design with dose selection (190 vs 230 mg/m2) adds complexity. AML in R/R setting after one prior line has poor prognosis. Complete remission after one cycle is a high bar; cytarabine backbone alone has limited efficacy here. No prior Phase 2 data disclosed for this specific combination. Long timeline (1204 days to completion) increases operational and disclosure risk. Sponsor MBRX is small-cap with limited AML development experience.

Relapsed/refractory AML after one prior line is a high-mortality population with poor prognosis. L-Annamycin is an anthracycline derivative with limited prior Phase 1/2 data in this exact setting. The adaptive design (Part A dose selection, Part B superiority) introduces execution risk—wrong dose selection dooms Part B. Complete remission after one cycle is a demanding endpoint in this refractory population. 312-patient size is modest for a pivotal claim. Sponsor MBRX is micro-cap with limited track record of pivotal trial execution. Long timeline (1206 days) adds operational and funding risk.

Adaptive Phase 2/3 trial in relapsed/refractory AML is methodologically rigorous (randomized, double-blind, placebo-controlled) but AML remains biologically challenging. No prior efficacy data provided. Early-stage with 312 enrollment and 1204 days to completion. Dose-finding Part A adds uncertainty. Conservative estimate given indication difficulty.

Relapsed/refractory AML is a high-risk indication with historically low response rates. L-Annamycin is an anthracycline with prior clinical data but faces stiff competition from newer agents (venetoclax, FLT3 inhibitors). The adaptive Phase 2/3 design is rigorous, but complete remission as endpoint in this difficult population is ambitious. Estimated 35% intrinsic probability.